|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Autoimmune
Diseases Research & Development
Our ongoing research in autoimmune diseases is primarily based
on cell trafficking and focuses on discovering disease-modifying
approaches to treating a wide range of autoimmune diseases,
including MS, CD and RA. Tysabri emerged from this
research program. We remain focused on discovering
disease-modifying approaches to treating a wide range of
autoimmune diseases, including MS, CD and RA. In 2006, we
expanded our research in autoimmune diseases to include novel
anti-inflammatory approaches in addition to our core alpha 4
integrin programs.
Since first publishing the hypothesis concerning the therapeutic
potential of blocking alpha 4 integrin in 1992, our scientists
have been expanding and refining our understanding of how cells
enter tissues. We now have a clear understanding of how cells
enter the gut, brain, or joints, and cause the damage
characteristic of MS, CD, and RA. Through the course of this
work we have developed small molecules that can selectively
block particular alpha 4 integrin interactions. The first drug
candidate evolving from this effort is ELND-001, which is in
Phase 1. Further work is ongoing for other molecules that
target the alpha 4 integrin pathway.
In June 2006, we entered into a multi-product alliance with
Archemix Corp. (Archemix) to discover, develop and commercialize
aptamer therapeutics for autoimmune diseases. This program is in
the discovery phase.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Autoimmune
Diseases Research & Development
Our ongoing research in autoimmune diseases is based primarily
on cell trafficking and focuses on discovering disease-modifying
approaches to treating a wide range of autoimmune diseases,
including MS, CD and RA. Tysabri emerged from this
research program.
Since first publishing the hypothesis concerning the therapeutic
potential of blocking alpha 4 integrin in 1992, our scientists
have been expanding and refining our understanding of how cells
enter tissues. We now have a clear understanding of how cells
enter the gut, brain, or joints, and cause the damage
characteristic of CD, MS, and RA. Through the course of this
work we have developed small molecules that can selectively
block particular alpha 4 integrin interactions, culminating in
the development of ELND001 and ELND002 - two alpha 4
integrin small molecule antagonists targeted at distinct
autoimmune diseases. We hope to bring these new therapies into
the clinic in 2006.
| EXCERPTS ON THIS PAGE:
|
| |||||||
